Changeflow GovPing Pharma & Drug Safety Catecholamine prodrugs, Parkinson's disease tre...
Routine Notice Added Final

Catecholamine prodrugs, Parkinson's disease treatment, Lundbeck

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3972971A1 for Lundbeck covering novel catecholamine prodrug compositions for treating Parkinson's disease. The A1 publication indicates the application passed formal examination and is now publicly available. The patent names Morten Jørgensen, Martin Juhl, and Klaus Jensen Gjervig as inventors.

What changed

The EPO published patent EP3972971A1 granting Lundbeck exclusive rights to catecholamine prodrug compositions for Parkinson's disease treatment. The patent covers A61P 25/16 therapeutic uses under IPC classification C07D 221/08 and C07H 17/02. The published claims define the prodrug chemical structure and its pharmaceutical applications.

For pharmaceutical companies and drug developers, this patent creates potential licensing opportunities or may necessitate design-around strategies for Parkinson's treatments in the European market. The designated states cover all EU member states plus Switzerland, Norway, and Turkey. Patent holders should monitor the nine-month opposition period following publication.

What to do next

  1. Monitor for patent validation in specific countries of interest
  2. Review claims for freedom-to-operate analysis

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES

Publication EP3972971A1 Kind: A1 Apr 01, 2026

Applicants

H. Lundbeck A/S

Inventors

JØRGENSEN, Morten, JUHL, Martin, JENSEN, Klaus, Gjervig

IPC Classifications

C07D 221/08 20060101AFI20251219BHEP C07H 17/02 20060101ALI20251219BHEP A61P 25/00 20060101ALI20251219BHEP A61P 25/16 20060101ALI20251219BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3972971A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent protection Drug development Pharmaceutical manufacturing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.